CAMBRIDGE, Mass. — ImmuVia Inc. has selected Quantori as a strategic technology partner to help accelerate development of its lead cancer therapy candidate, IMV-M™, the company said.
Under the agreement, ImmuVia will deploy Quantori’s Q-Scientist platform to streamline computational workflows across its preclinical programs, aiming to shorten development timelines and reduce costs as it advances the therapy toward clinical trials.
IMV-M™ is a bispecific antibody developed using ImmuVia’s proprietary Cancerlysin™ platform. The therapy is designed to selectively trigger cancer cell death by first binding to MUC16, a protein overexpressed in several solid tumors, including ovarian and pancreatic cancers, and then activating a pathway that induces apoptosis.
Death receptor agonists have long been considered a promising approach in oncology, but prior efforts have struggled due to limited effectiveness or safety concerns. ImmuVia said its approach is designed to improve both potency and selectivity.
Rather than building internal computational capabilities, the company will rely on Quantori’s platform to support molecular modeling, pharmacokinetic simulation and regulatory data preparation.
The partnership will focus on three areas: modeling how the therapy binds to targets to reduce the need for repeated laboratory experiments, simulating how the drug behaves in the body and tumor environments, and organizing data for regulatory submissions to speed up development timelines.
“ImmuVia is a biology company. Our edge is the science behind IMV-M™ and the Cancerlysin™ platform,” said Iosif M. Gershteyn, Chief Executive Officer at ImmuVia. “What we need from technology partners is straightforward: help us do our work faster and at lower cost. Quantori’s platform does exactly that. It lets a lean team operate with the analytical throughput of a large organization, that’s a practical advantage we intend to leverage.”
Yuriy Gankin, Ph.D., Chief Scientific Officer at Quantori, said the collaboration highlights the growing role of computational tools in drug development.
“What makes this collaboration compelling is the quality of the underlying science,” Gankin said. “ImmuVia’s platform represents a genuinely differentiated approach to harnessing the biology of apoptosis, and the computational demands of a program this sophisticated are exactly where Q-Scientist delivers the most value. We can construct detailed in silico models of IMV-M’s behavior — its conformational dynamics, its interactions within the tumor microenvironment — and deliver those insights at a speed and cost that would be impossible to replicate through traditional methods.”
